Gilead's Descovy AdCom gets 'controversial' by Carly Helfand Wednesday, August 7, 2019 Gilead’s Descovy secured backing from an FDA panel for HIV prevention in men and transgender women. But beyond that, it ran into issues.
FDA reviewers back Descovy for PrEP in men. What about women? by Carly Helfand Tuesday, August 6, 2019 As FDA panel experts gear up to debate the merits of Gilead’s Descovy for PrEP, the question isn't whether it’s worthy of an indication in men.
